Brain Cancer | Specialty

The OncLive Brain Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of brain cancer, including glioma, glioblastoma multiforme, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

Silevertinib Drives CNS Responses in First-Line NSCLC With Non-Classical EGFR Mutations

December 3rd 2025

Silevertinib produced responses in NSCLC harboring non-classical EGFR mutations and will also be investigated in newly diagnosed glioblastoma.

Dr Brown Discusses Neuroendocrine Tumors

December 3rd 2025

Rebecca Brown, MD, PhD, discusses neuroendocrine tumors.

IGV-001 Prolongs OS vs Placebo in Newly Diagnosed Glioblastoma

December 2nd 2025

IGV-001 produced an OS benefit vs placebo in newly diagnosed glioblastoma.

Real-World Data Shows Vorasidenib Could Address Earlier Treatment Needs in IDH-Mutant Glioma

November 29th 2025

Study findings indicate potential unmet needs for early vorasidenib treatment with minimal toxicity for patients with slow-growing IDH-mutant gliomas.

Tovorafenib Yields Long-Term Efficacy in Pediatric Low-Grade Glioma: With Cassie Kline, MD, MAS

November 27th 2025

Dr Kline discusses longer-term efficacy data from the FIREFLY-1 study of tovorafenib in patients with relapsed/refractory pediatric low-grade glioma.

Vorasidenib Demonstrates Favorable Safety Profile and Disease Stability in High-Grade IDH-Mutant Gliomas

November 27th 2025

Retrospective data showed vorasidenib displayed strong disease stability in addition to being well tolerated in grade 3 or 4 IDH-mutant glioma.,

Intraventricular B7-H3–Targeted CAR T-Cell Therapy Displays Safety in Recurrent Glioblastoma

November 25th 2025

B7-H3–directed CAR T cell therapy was well-tolerated and demonstrated an acceptable safety profile in recurrent glioblastoma.

Vorasidenib Reduces Tumor Growth Rate in IDH1/2-Mutant Grade 2 Glioma

November 24th 2025

INDIGO TGR analyses showed vorasidenib markedly slowed tumor growth and improved PFS and TTNI vs placebo in IDH1/2-mutant grade 2 glioma.

Sequential ICV/IV C7R-GD2 CAR T-Cell Therapy Is Better Tolerated in Pediatric CNS Tumors

November 24th 2025

Sequential intracerebroventricular and intraventricular administration of CAR T-cell therapy was better tolerated in pediatric central nervous system tumors.

Vorasidenib Shows Rapid Real-World Uptake in IDH-Mutated Glioma

November 24th 2025

Vorasidenib is being integrated in the real-world setting for the treatment of patients with IDH-mutated glioma.

18F-Fluciclovine Imaging Differentiates Progression From Treatment-Related Changes in Brain Metastases

November 23rd 2025

18F-Fluciclovine PET/MRI detected disease progression and ruled out disease in non-progressors among patients with solid tumor brain metastases.

Lutetium Lu 177 Dotatate Shows Promise in Advanced Intracranial Meningioma

November 23rd 2025

Phase 2 study finds 177Lu-Dotatate safe in advanced intracranial meningioma, with a 6-month PFS rate surpassing historical benchmarks.

Erdafitinib Is Safe and Shows Preliminary Efficacy in F3T3 Fusion+ Glioma

November 23rd 2025

Erdafitinib had a safety profile that was deemed tolerable in patients with recurrent or progressive IDH wild-type glioma harboring F3T3 gene fusions.

Eflornithine Plus Lomustine Extends PFS, OS in Reclassified WHO Grade 3 IDH-Mutated Astrocytoma

November 23rd 2025

Eflornithine plus lomustine produced superior OS and PFS outcomes vs lomustine in WHO grade 3 IDH-mutated astrocytoma.

Temozolomide Plus Radiotherapy Yields Survival Benefit in IDH-Mutant LGG

November 23rd 2025

Temozolomide plus radiotherapy significantly improved OS vs radiotherapy alone in IDH-mutant low-grade gliomas without codeletions of 1q and 19q.

Mirdametinib Shows Improved ORR Over Time in NF1-Associated Symptomatic Plexiform Neurofibroma

November 22nd 2025

Long-term ReNeu results showed deeper, more durable responses to mirdametinib in NF1-PN with extended treatment in both adults and children.

CAR T-Cell Therapy Shows Early Safety in Recurrent Brain/Leptomeningeal Mets From HER2+ Breast Cancer

November 22nd 2025

HER2-directed CAR T-cell therapy was safe in patients with brain/leptomeningeal metastases from HER2-positive breast cancer.

B7-H3–Directed CAR T-Cell Therapy Has Acceptable Safety Profile in Recurrent Glioblastoma

November 22nd 2025

B7-H3–directed CAR T-cell therapy given intraventricularly was well tolerated and showed early efficacy signals in patients with recurrent glioblastoma.

Mirdametinib Generates Responses and Is Safe in Pediatric Low-Grade Glioma

November 22nd 2025

Mirdametinib had clinical activity and was deemed well tolerated in MEK inhibitor–naive pediatric patients with recurrent/progressive low-grade glioma.

Regorafenib Plus Temozolomide and RT Shows Early Signs of Tolerability in MGMT-Methylated, IDH Wild-Type Glioblastoma

November 22nd 2025

The RP2D of regorafenib when given with temozolomide and radiotherapy in patients with MGMT-methylated, IDH wild-type glioblastoma was 120 mg.